Introduction
Rheumatoid arthritis (RA) is a chronic and disabling disease characterized by persistent synovitis and systemic inflammation, in which over-expression of tumour necrosis factor (TNF) and interleukin (IL)-1b drive both synovial inflammation and joint destruction [1] . It is well known that RA is associated with an increased mortality rate due to the increased risk of cardiovascular (CV) events when compared with the general population [2] [3] [4] [5] , and related to the chronic inflammatory process, which is able to modulate an accelerated atherosclerosis and CV disease (CVD) [6] . Both atherosclerosis and RA share common inflammatory pathways, mediated mainly by TNF and IL1b [7] [8] [9] . In fact, increased levels of TNF and IL-1b may promote endothelial dysfunction, structural vessel abnormalities, oxidative stress and changes in lipid levels, thus favouring the appearance of traditional CV risk factors such as hypertension, insulin resistance and type 2 diabetes (T2D) [2, 10, 11] . It is well known that patients affected by T2D show a higher CV morbidity and mortality when compared with non-diabetic subjects [12] . In addition, the diabetic vascular alterations may be responsible for both diffuse coronary artery disease and stroke, which are increased significantly in T2D patients, and the risk for the occurrence of a CV event in these patients, without a previous history of CVD, mirrors the CV risk observed in patients with a history of previous myocardial infarction [13, 14] . On this basis, we understand why patients affected by both RA and T2D displayed the highest risk for CVD and related mortality [15, 16] , as suggested by a prospective cohort study, conducted in the setting of the CORRONA registry (Comparative Effectiveness of Biologic and Oral Agents for the Treatment of Rheumatoid Arthritis), aimed at investigating the association between CVD and RA showing that both T2D and RA may contribute to increasing the severity of CVD and in predicting the risk of fatal CV events [17] . At present, a growing body of evidence shows the positive association between RA and T2D: different databases, from clinical studies and from national registers, confirmed that RA patients displayed a double risk of developing T2D when compared with the general population [18] [19] [20] , and epidemiological data strongly support the association between RA and insulin resistance [21, 22] .
In recent years, many papers have supported the role of inflammatory mechanisms in the pathogenesis of T2D [23] and recently, as already described for type 1 diabetes mellitus (T1D), the pathogenetic role of insulitis in T2D has been proposed [23] [24] [25] [26] . Although the precise aetiology of the insulitis in both types of diabetes remains to be understood fully, some specific differences have been described. At present we know that the T1D insulitis is driven by an autoimmune process, whereas in T2D it is linked to an autoinflammatory process, involving the IL-1b pathway [23, 24] .
Although different cell types may produce IL-1b, this cytokine is produced mainly by monocytes which, as shown by preclinical and clinical studies, may be involved in the pathogenesis of both these diseases [27, 28] . Different pathological stimuli are able to modulate the assembly of a cytosolic platform, the inflammasome, composed of at least five different protein components integral to this complex, including nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3), caspase recruitment domain containing protein 8 (CARD8), pyrin, apoptosis-associated speck-like protein containing CARD (ASC) and pro-caspase-1, which is involved mainly in host defence against microbes and where the inactive pro-IL-1b is cleaved into a small, mature, active form [29, 30] . NLRP3-inflammasome is also activated by host-derived metabolites, such as monosodium urate crystals, cholesterol crystals and free fatty acids, and involved in the development of some inflammatory diseases such as gout, atherosclerosis and T2D [23] [24] [25] [26] [27] [28] [29] [30] .
Of interest, it must be pointed out that recently, in RA patients, a significantly higher gene expression of ASC, NLRP3 and CASP1, associated with an increase of caspase-1 and IL-18 levels, was observed, suggesting that this upregulation of NLRP3-inflammasome-related transcripts may reflect an increased inflammasome activity [31] , and supports the hypothesis that autoinflammatory pathways may play a pathogenetic role in both diseases.
In this study, we evaluated the production of IL-1b, TNF, and NLRP3 expression in peripheral blood monocytes (MO) of patients affected by both RA and T2D, after exposure to different glucose concentrations, to assess the influence of altered glucose metabolism on their proinflammatory status.
Patients and methods

Patients
Between January 2010 and December 2014 we enrolled 10 RA patients, 10 T2D patients and 10 patients affected by both diseases (T2D/RA patients), according to standard criteria [32, 33] , and five healthy controls (HC). Demographic and clinical features were summarized in Table 1 . T2D patients were eligible if the disease duration was more than 3 months but less than 1 year, the glycated haemoglobin value between >7Á0 and < 9Á0% at screening time and no changes in diabetes medications within the last 3 months. RA patients were eligible if their disease duration was diagnosed from more than 3 months and receiving only symptomatic therapy [non-steroidal antiinflammatory drugs (NSAIDs)]. At the time of enrolment no patient showed signs and/or symptoms of early atherosclerosis or CVD, as assessed by flow-mediated dilation of the brachial artery and by intimamedia thickness, transthoracic Doppler and tissue Doppler echocardiography, aortic root echocardiography and pulse-wave velocity and colour Doppler ultrasounds of the neck vessels. Furthermore, no patient showed clinical and laboratory parameters compatible with the diagnoses of metabolic syndrome, essential hypertension, hypercholesterolaemia or hypertriglyceridaemia. Finally, no patient had smoking and alcohol habits.
An independent ethics committee approved the study and all subjects provided written informed consent before participation; the protocol was according to the Declaration of Helsinki.
Monocyte preparations
Human peripheral blood mononuclear cells (PBMCs) were isolated from heparinized blood using Ficoll-Hypaque gradients (Histopaque-1077; Sigma, St Louis, MO, USA). MO were isolated from PBMCs either by positive selection using magnetic CD14 MicroBeads (human; Miltenyi Biotech, Bergisch Gladbach, Germany), according to the manufacturer's instructions. Following isolation, MO from our patients and controls were washed three times in phosphatebuffered saline, suspended in RPMI-1640 medium (GIBCO/ BRL, Grand Island, NY, USA) containing 10% heatinactivated autoserum, 1 3 10 5 IU/1 penicillin (GIBCO/BRL), 100 mg/1 streptomycin (GIBCO/BRL) and 1000 p-mol/ 1 L-glutamine (GIBCO/BRL) and seeded into autoserumcoated culture plates (Nunclon; Nunc, Roskilde, Denmark). Aliquots of 1 3 10 6 MO were suspended in 1 ml of complete medium seeded into 24-well culture dishes (Falcon 3047; Becton Dickinson, Parsippany, NJ, USA) and incubated with 11 mmol/1 glucose (11G) and 33 mmol/1 glucose (33G) for 24 h in a humidified 5% CO 2 incubator at 378C. The choice of 11G was suggested by the observation that, in humans, glucose is degraded continuously and formed in order to maintain a stable concentration of 5 mmol/1 in the bloodstream. However, in our cell cultures, where glucose is metabolized but not replaced, cells incubated with a concentration of 5 mmol/1 glucose for 24 h metabolized this molecule strongly, lowering the concentration to less than 2 mmol/1. For this reason, we chose a concentration of 11G, as in our experience a glucose concentration of 11G does not lead to glucose deficiency after 24 h of incubation. In high glucose studies, cells were exposed to a high glucose concentration of 33G. Many previous studies have reported that glucose concentrations as high as 50 mmol/1 have been found in the blood of patients with uncontrolled diabetes [34, 35] . It is true that blood glucose levels in patients are not likely to remain as high as 33G for 24 h. However, tissue damage in diabetic patients occurs over many years of countless hyperglycaemic episodes. Thus, the glucose concentration of 33G used in this cell culture study does not seem unreasonable, as observed in previous work [35] . Lipopolysaccharide (2 ng/ml) was used to stimulate the secretion of cytokines in cell culture. Media were collected and stored after 24 h of incubation for the IL-1b and TNF using a specific enzyme-linked immunosorbent assay (ELISA).
Measurement of IL-1b and TNF levels by ELISA
The amounts of IL-1b and TNF released in the supernatants were determined by using specific Quantikine Human Immunoassay ELISA kits (all by R&D Systems, Minneapolis, MN, USA), according to the manufacturer's protocol. Our results were expressed as median (range). For circulating levels of IL-1b and TNF, sera were collected from patients and HC and tested by the same ELISA assays used for MO culture.
qRT-PCR analysis
RNA were extracted from collected MO using Trizol (Sigma, St Louis, MO, USA) and reverse-transcribed into complementary DNA (cDNA) with the ThermoScript reverse transcription-PCR system (Invitrogen, Carlsbad, CA, USA). Results were analysed after 40 cycles of amplification using the ABI 7500 Fast Real Time PCR System. IL-1b, TNF and NLRP3 gene expression were assessed by commercial TaqMan gene expression assay (Hs01555410_m1, Hs01113624_g1 and Hs00918082_m1, respectively). All gene expression data were normalized to those for glyceraldehyde 3-phosphate dehydrogenase (GAPDH).
Western blot
Human MO were washed three times with cold Ca 21 -free and Mg-free phosphate-buffered saline (PBS) and lysed by NP-40 lysis buffer (Boston Biosciences, Ashland, MA, USA) containing 150 mM phenylmethanesulphonylfluoride (PMSF) (Fluka Biochemika-Sigma Aldrich, St Louis, MO, USA) and 1% protease inhibitor cocktail [dissolved in dimethylsulphoxide (DMSO), Sigma Aldrich]. Lysates were centrifuged and protein concentrations in supernatants were determined using the bicinchoninic acid (BCA) assay (Pierce, Rockford, IL, USA). Equal amounts of protein were added to the sodium dodecyl sulphide (SDS) sample buffer containing 2-mercaptoethanol (without boiling), and electrophoresed on SDS-polyacrylamide gels.
Gels were blotted on nitrocellulose membrane (Invitrogen). Blots were blocked overnight in TTBS (TBS-buffer containing 5% milk powder and 0.05% Tween-20). Blots were incubated with primary antibodies [room temperature (RT), 1 h, TTBS], washed three times with TTBS and then probed with secondary horseradish peroxidase (HRP)-linked antibodies (RT, 1 h, TTBS; GE Healthcare, Piscataway, NJ, USA). After repeated washes, blots were developed by chemiluminescence using the Lumigen DS detection kit (GE Healthcare). The primary antibodies used were: NLRP3 (R&D Systems). All the signals were 
Statistical analysis
GraphPad Prism version 5Á0 software was used for statistical analyses. Results are expressed as median (range). Due to the non-parametric distribution of our data the MannWhitney U-test was used as appropriate for analyses. Despite the small numbers of patients enrolled into each studied group, the strong a priori evidence of an increased NLPR3 activation associated with both RA and T2D [24, 29, 31 ] allowed us to not apply Bonferroni's correction in our statistical analyses. Statistical significance was expressed by a P-value < 0Á05.
Results
Increased secretion of IL-1b after high concentration glucose stimulation in supernatants of cultured cells
Our data showed that, after 24 h of incubation with 11G, a significant increase of IL-1b levels was shown when T2D, RA and T2D/RA patients were compared with HC [HC: 4Á5 (4Á1; 5Á8) pg/ml; T2D: 48Á0 (20Á1; 63Á6) pg/ml; RA: 55Á0 (34Á5; 105Á2); T2D/RA: 54Á5 (32Á5; 102Á4) pg/ml; P < 0Á01 for each comparison]. Furthermore, no significant differences in IL-1b levels were observed among patient groups. On the contrary, after 24 h of incubation with 33G a significant increase in IL-1b levels were observed in the supernatants of T2D/RA patients when compared with HC and among other evaluated groups [HC: 135Á3 (108Á1; 256Á8) pg/ml; T2D: 208Á2 (123Á1; 300Á6) pg/ml; RA: 201Á0 (168Á5; 208Á2) pg/ml; T2D/RA 352Á5 (257Á5; 711Á9) pg/ml; P < 0.01 for each comparison]. No significant differences were observed when we compared RA patients and T2D patients with HC. Our results showed that, after 24 h of incubation with 11G, a significant increase in TNF levels was shown when T2D, RA and T2D/RA patients were compared with HC [HC: 21Á4 (20Á2; 23Á6) pg/ml; T2D: 356Á1 (234Á1; 695Á3) pg/ml; RA: 437Á5 (356Á5; 970Á2) pg/ml; T2D/RA: 496Á2 (426Á7; 770Á5) pg/ml in T2D/RA patients; P < 0.01 for each comparison].No significant differences in TNF levels were observed among patient groups. Our data showed that, after 24 h of incubation with 33G, a significant increase in TNF levels was shown when T2D, RA and T2D/RA patients were compared with HC [HC: 135Á4 (108Á2; 256Á3) pg/ml; T2D: 733Á5 (500Á2; 1008Á1) pg/ml; RA: 778Á5 (570Á1; 1007Á0) pg/ml; T2D/RA: 800Á4 (437Á1; 1130Á6) pg/ml; P < 0.01 for each comparison]. No significant differences in TNF levels were observed among patient groups. These results are summarized in Fig. 1 .
Increased expression of IL-1b after high concentration glucose stimulation
Our data showed that, after 24 h of incubation with 11G, a significant increase in relative IL-1b mRNA expression was reported when T2D, RA, and T2D/RA patients were compared with HC [HC: 1Á5 (1Á0; 2Á0); T2D: 5Á2 (4Á5; 6Á9); RA: 4Á8 (3Á2; 6Á2); T2D/RA 5Á7 (4Á5; 6Á9) patients; P < 0Á01 for each comparison]. No significant differences in relative IL1b mRNA expression were observed among patient groups. However, after 24 h of incubation with 33G a significant increase in relative IL-1b mRNA expression was observed in the supernatants of T2D/RA patients when compared with HC and among other evaluated groups [HC: 3Á2 (2Á0; 5Á7); T2D: 14Á5 (12Á0; 18Á0); RA: 15Á8 (14Á2; 19Á4); T2D/ RA: 24Á3 (20Á0; 27Á2); P < 0Á001 for each comparison]. Significant differences were observed when we compared both RA patients and T2D patients with HC (P < 0.01 for each comparison).
Our results showed that, after 24 h of incubation with 11G, a significant increase of relative TNF mRNA expression was shown when T2D, RA and T2D/RA patients were compared with HC [HC: 1Á2 (1Á0; 2Á2); T2D: 5Á7 (4Á5; 6Á8); RA: 6Á2 (4Á8; 9Á0); T2D/RA: 5Á8 (4Á5; 7Á6); P < 0Á001 for each comparison]. Our work showed that, after 24 h of incubation with 33G, a significant increase of relative TNF mRNA expression was shown when T2D, RA and T2D/RA patients were compared with HC [HC: 6Á2 (6Á0; 7Á2); T2D: 14Á7 (14Á1; 18Á2);RA: 15Á8 (14Á0; 18Á0); T2D/RA: 15Á5 (14Á8; 18Á6); P < 0Á01 for each comparison]. No significant differences in TNF levels were observed among patient groups. All these data are reported in Fig. 2 .
Increased expression of NLRP3-inflammosome in T2D/RA patients
After 24 h of incubation to 11G our results showed a significant increase in relative NLRP3 mRNA expression of T2D/ RA patients when compared with other groups [HC: 1Á2 (1Á0; 2Á0); T2D: 5Á1 (4Á5; 7Á9); RA: 3Á6 (3Á2; 5Á9); T2D/RA: 7Á5 (6Á9; 10Á9); P < 0Á001 for each comparison]. In addition, we reported a significantly higher relative NLRP3 mRNA expression when compared T2D and RA patients with HC (P < 0Á01 for each comparison). A significantly higher relative NLRP3 mRNA expression in T2D patients with respect to RA patients was shown (P < 0Á01) at the same glucose concentration. After 24 h of incubation with 33G our results showed a significant increase in relative NLRP3 mRNA expression when we compared T2D/RA patients to other groups [HC: 4Á2 (2Á0; 5Á0); T2D: 16Á4 (15Á4; 18Á8); RA: 13Á8 (10Á0; 18Á0); T2D/RA: 22Á8 (20Á9; 27Á0); P < 0Á001 for each comparison]. We described a significantly higher relative NLRP3 mRNA expression when we compared T2D and RA patients with HC (P < 0Á01 for each comparison). A significantly higher relative NLRP3 mRNA expression in T2D patients in respect to RA patients was shown (P < 0Á01) at the same glucose concentration. These data were confirmed by Western blot analyses. This analysis mirrored the results obtained by evaluation of NLRP3 mRNA expression; Fig. 3 shows these findings.
No differences in circulating levels of IL-1b and TNF were observed
When we analysed the circulating levels of IL-1b among enrolled patients we did not find significant differences [HC: 1Á5 (1Á1; 1Á8) pg/ml; T2D: 1Á1 (1Á2; 1Á8) pg/ml; RA: 5Á9 (1Á5; 2Á8) pg/ml; T2D/RA: 1,9 (1Á5;2Á3) pg/ml]. Similarly, the analysis of the circulating levels of TNF among enrolled patients did not show significant differences [HC: 2Á9 (0Á2; 3Á6) pg/ml; T2D: 2Á8 (1Á2; 3Á9) pg/ml; RA: 2Á7 (0Á5; 4Á1) pg/ml; T2D/RA: 3Á1 (0Á4; 4Á6) pg/ml].
Discussion
In recent years, the involvement of innate immunity has been suggested in the pathogenesis of T2D [23] [24] [25] [26] [27] [28] [29] [30] , and several studies have described elevated circulating levels of acute-phase proteins, cytokines and chemokines in patients with T2D, and elevated levels of IL-1b, IL-6 and C-reactive protein have been suggested as predictive factors of T2D development [36] [37] [38] [39] . In addition, an immune cell infiltration surrounding the pancreatic islets in human T2D, characterized largely by MO, may be observed [39] . On this basis, a better knowledge of the metabolically driven inflammation observed in T2D may open future perspectives, identifying new potential biomarkers and/or new therapeutic targets [23] [24] [25] [26] [27] [28] [29] [30] . In this regard, several papers have suggested, both in experimental models and in humans, the usefulness of cytokine antagonism therapies Monocytes were incubated with 11 mmol/1 glucose (11G) and 33 mmol/1 glucose (33G) for 24 h. Our data showed that, after 24 h of incubation with 11G, a significant increase of relative IL-1b and TNF mRNA expressions were reported when type 2 diabetes (T2D), rheumatoid arthritis (RA) and T2D/RA patients were compared with healthy controls (HC) (P < 0Á001 for each comparison). However, after 24 h of incubation with 33G a significant increase in relative IL-1b mRNA expression was observed in the supernatants of T2D/RA patients when compared with HC and among other evaluated groups (P < 0Á01 for each comparison) (***P < 0Á001). Our data showed that, after 24 h of incubation with 11G, a significant increase of IL-1b and TNF levels were shown when type 2 diabetes (T2D), rheumatoid arthritis (RA) and T2D/RA patients were compared with healthy controls (HC) (P < 0Á01 for each comparison). After 24 h of incubation with 33G, a significant increase in IL-1b levels were observed in the supernatants of T2D/RA patients when compared with all evaluated groups (P < 0Á01 for each comparison) (**P < 0Á01).
T2D/RA monocytes and IL-1b production V C 2015 British Society for Immunology, Clinical and Experimental Immunology, 182: [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] in T2D, mirroring what has been suggested for RA and other inflammatory arthritis [23, 24] .
In this paper, we show that increased concentrations of glucose strongly influence the proinflammatory status of MO derived from patients affected by RA and concomitant T2D, suggesting that the altered glucose metabolism, increasing the production of inflammatory cytokines, may affect the clinical picture of RA and influences the response to targeted therapies [1, 2, 5, [8] [9] [10] .
After incubation of MO with different glucose concentrations, we observed an increased production of IL-1b in any studied subset correlating directly with glucose concentrations, the highest levels observed in patients affected by both diseases. It is well known that hyperglycaemia levels may up-regulate the expression of different transcription factors of many proinflammatory cytokine genes [40] [41] [42] . Among them, the transcription factor nuclear factor (NF)-jB may mediate the increased IL-1b secretion from MO exposed to hyperglycaemic conditions [43, 44] . Analyses of IL-1b mRNA confirmed these results, showing a significant increase of its expression in T2D/RA patients when compared with other groups.
It is well known that, during T2D, the polarity of isletinfiltrating MO is shifted towards the activated proinflammatory M1-type, releasing higher concentrations of IL-1b [45] . Experimental models of T2D showed that during euglycaemic conditions MO exhibit a M2-type phenotype, promoting wound healing and modulating immune responses. Conversely, under the influence of hyperglycaemia, these M2-type MO shift to a M1-type phenotype, starting the production of inflammatory cytokines such as IL-1b, and leading to a fibrotic degeneration associated with amyloid deposits of Langerhans islets [27, 45] . In this setting, the higher levels of IL-1b have been shown to drive the progressive failure of insulin production and apoptosis of b cells [46, 47] . Furthermore, glucose-induced IL-1b production by MO involved up-regulation of the NLRP3-inflammasome [48] . Higher concentrations of glucose may induce the dissociation of thioredoxin-interacting protein (TXNIP) from thioredoxin, under the influence of reactive oxygen species, allowing the binding of TXNIP to the NLRP3-inflammasome. This event leads to the activation of caspase-1 and subsequent release of mature IL-1b from inactive pro-IL-1b [49] . Interestingly, confirming the results concerning IL-1b production, a significantly higher expression of NLRP3-inflammasome was observed after incubation with different glucose concentrations in T2D/ RA patients when compared with the other groups. Regarding the role of NLRP3-inflammasome in glucose and insulin homeostasis, several preclinical studies showed that the genetic deletion of NLRP3 in high-fat diet-fed mice improved glucose tolerance and enhanced insulin sensitivity [50, 51] . These data were confirmed in NLRP3 2/2 knock-out animals, where the IL-1b levels in the adipose tissue decreased significantly; this reduction is associated with lower levels of caspase-1 activity [51] . Furthermore, inhibition of NLRP3-inflammasome is associated with improved insulin signalling in adipose tissue, liver and skeletal muscles, which are considered insulin-sensitive tissue, and with increased insulin secretion from b islets [50] [51] [52] [53] .
Our data also showed increased production of TNF from MO obtained from T2D/RA, T2D and RA patients after exposure to different glucose concentrations when compared to HC, although no significant difference was observed among the studied subsets. The available literature reports that the expression of TNF in adipose tissue was increased in multiple rodent obesity models, and this cytokine may decrease insulin signalling in insulin-sensitive tissues [54] [55] [56] . Furthermore, in these experimental models, weight loss may induce an improvement in insulin sensitivity that has been associated with a reduction in TNF expression [54] [55] [56] [57] . According to these experimental Fig. 3 . Increased relative expression of nucleotide-binding domain and leucine-rich repeat containing family pyrin (NLRP3) (a) after glucose stimulation and Western blot analyses (b). Monocytes were incubated with 11 mmol/1 glucose (G11), 33 mmol/1 glucose (G33). The expression levels of healthy controls (HC) incubated with 11 mmol/1 glucose (G11) were set to 100%, and the results were normalized to this value. Tubulin was measured as a loading control for normalization. After 24 h of incubation to 11G our results showed a significant increase in relative NLRP3 mRNA expression in type 2 diabetes/rheumatoid arthritis (T2D/RA) patients when compared with other groups (P < 0Á001 for each comparison). After 24 h of incubation to 33G the results showed a significant increase in relative NLRP3 mRNA expression when we compared T2D/RA patients to other groups (P < 0Á001 for each comparison). This analysis mirrored the results obtained by evaluation of NLRP3 mRNA expression by Western blot (**P < 0Á01; ***P < 0Á001, respectively).
findings, studies using TNF 2/2 knock-out mice, or alternatively neutralizing TNF activity by specific antibodies, showed an improvement in glycaemia levels, suggesting TNF as potential therapeutic target for T2D [54] [55] [56] [57] . Despite the experimental evidence supporting a role for TNF in regulating insulin production and function, the translation from basic researches to the clinical setting by using TNF inhibitors in the treatment of human diabetes showed disappointing results [58] [59] [60] . Although further studies are needed to understand more clearly the failure of TNF inhibition in human diabetes, it must be pointed out that the intracellular TNF concentration is responsible for insulin resistance via paracrine effects, and this intracellular cytokine cannot be blocked by TNF inhibitors [61] .
In contrast, several published studies suggest the possible therapeutic role of IL-1 antagonism in T2D [62, 63] . In this context, 70 T2D patients, assigned randomly to receive 100 mg of anakinra, an IL-1 receptor antagonist licensed for RA or placebo, showed a significant decrease in the glycated haemoglobin level and an increase of C-peptide secretion after 13 weeks of treatment [64] . The follow-up of these patients showed that this improvement was still detectable 39 weeks after discontinuation of anakinra [65] . Furthermore, the results of a 1-year prospective observational study enrolling 470 RA patients treated with anakinra showed that RA patients with concomitant T2D displayed a better response to this drug [66] . These data suggest that T2D comorbidity in RA patients predicts those patients with a better response to IL-1 inhibition. In addition, different papers suggest that IL-1 blockade may be helpful in patients with T2D and inflammatory rheumatic diseases [67, 68] . On this basis, an open, randomized, controlled, double-armed, multi-centre study, whose primary end-point is the efficacy of anakinra in controlling signs and symptoms of T2D in RA patients and T2D co-morbidity, is ongoing (TRACK study, NCT02236481, www.clinicaltrial.gov).
It is well known that both T2D and RA are independent factors increasing the risk of CV events in affected patients and these data are related to the chronic inflammatory activity observed in both diseases, mediated by the overproduction of inflammatory cytokines [16, 17, 23, 24, 28] . In addition, a large body of preclinical data showed that IL-1b is involved strongly in the progression of atherosclerosis [69, 70] . During the inflammatory process occurring in RA, it has been shown that TNF may contribute to endothelial dysfunction [71] . However, conflicting results have been published concerning the possibility that an anti-TNF therapy might restore normal endothelial function [72, 73] . Furthermore, it has been shown recently that the decrease of inflammatory markers, after anti-TNF treatment, were not associated with an improvement in vascular function [74, 75] . On the contrary, different works suggest that the IL-1 inhibition may be associated with a greater improvement of endothelial function in RA patients [76, 77] . Heart failure is a common evolution of atherosclerosis, and several studies have shown the safety and the usefulness of anti-IL-1 treatment in this condition, a clinical setting in which anti-TNF treatment is contraindicated [78] [79] [80] [81] . It is well known that the incidence of impaired cardiac function is increased strongly both in RA and T2D, leading to a poor prognosis [82, 83] . In this context, our experimental data, showing a strong up-regulation of IL-1b MO derived from patients with both RA and T2D, may support the hypothesis that blocking IL-1b may be considered the best therapeutic strategy to treat these patients, due to the upregulation of this cytokine in these patients and to the safety shown during chronic heart failure. On this basis, the scientific community is still waiting for the results of the CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcome Study) trial, a study planned to test the hypothesis that the inhibition of IL-1b by Canakinumab, a human IL-1b blocking monoclonal antibody, might reduce CV events in T2D [84, 85] .
IL-1 blocking agents are generally considered safe drugs. Although the occurrence of upper-airway infections may increase in patients receiving anti-IL-1 therapy, as observed with the other biological agents, the lack of opportunistic and tuberculosis infections confirms their safety profile [86, 87] .
In conclusion, although further studies are needed to understand fully the complex interplay between inflammation and metabolic disorders and consequent therapeutic implications, our study, showing an increased production of IL-1b by MO obtained from patients affected by both RA and T2D via NLRP3-inflammasome activation, supports the potential role of IL-1b-targeted therapy in these patients. literature search, paper revision and acceptance; G.T.: data collection, data interpretation, literature search, paper revision and acceptance; R.G.: study design, data interpretation, writing, paper revision and acceptance. All authors gave final approval for submitting the manuscript for review and agree to be accountable for all aspects of the work.
